Blood samples were collected in Vacutainer cell preparation tubes (BD Biosciences, Madrid, Spain) at baseline and at each clinical visit during the 24 months of follow-up. We analysed samples from the CUV, IV and VF groups drawn at months 0, 6, 12, 18 and 24 of mtDRV/rtv treatment. Moreover, the IA
profile changes in patients with blips and VF episodes were intensively analysed before each episode, at the moment of the viral rebound, and after each episode.